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Abstract
The term “motor neuron disease” encompasses a spectrum of disorders in which motor neu-
rons are the primary pathological target. However, in both patients and animal models of
these diseases, not all motor neurons are equally vulnerable, in that while some motor neu-
rons are lost very early in disease, others remain comparatively intact, even at late stages.
This creates a valuable system to investigate the factors that regulate motor neuron vulnera-
bility. In this study, we aim to use this experimental paradigm to identify potential transcrip-
tional modifiers. We have compared the transcriptome of motor neurons from healthy wild-
type mice, which are differentially vulnerable in the childhood motor neuron disease Spinal
Muscular Atrophy (SMA), and have identified 910 transcriptional changes. We have com-
pared this data set with published microarray data sets on other differentially vulnerable motor
neurons. These neurons were differentially vulnerable in the adult onset motor neuron dis-
ease Amyotrophic Lateral Sclerosis (ALS), but the screen was performed on the equivalent
population of neurons from neurologically normal human, rat and mouse. This cross species
comparison has generated a refined list of differentially expressed genes, including CELF5,
Col5a2, PGEMN1, SNCA, Stmn1 and HOXa5, alongside a further enrichment for synaptic
and axonal transcripts. As an in vivo validation, we demonstrate that the manipulation of a sig-
nificant number of these transcripts can modify the neurodegenerative phenotype observed
in a Drosophila line carrying an ALS causing mutation. Finally, we demonstrate that vector-
mediated expression of alpha-synuclein (SNCA), a transcript decreased in selectively vulner-
able motor neurons in all four screens, can extend life span, increase weight and decrease
neuromuscular junction pathology in a mouse model of SMA. In summary, we have combined
multiple data sets to identify transcripts, which are strong candidates for being phenotypic
modifiers, and demonstrated SNCA is a modifier of pathology in motor neuron disease.
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Author summary
The term “motor neuron disease” refers to a group of disorders, causing progressive paral-
ysis of affected patients due to the degeneration of motor neurons cells which control vol-
untary movements. Importantly, not all motor neurons appear to be affected in the same
way, with those that control the face being affected less that those that control the abdo-
men. The reason why some motor neurons are more vulnerable is unknown; however,
understanding this may provide new targets for therapeutics to slow motor neuron degen-
eration either as stand-alone therapeutics or in combination with SMN-inducing com-
pounds. In this study, we analysed gene expression in different groups of motor neurons
and compared this to previously published expression data to identify commonalities.
One of the common transcripts was alpha-synuclein (SNCA), which was consistently
expressed at lower levels in vulnerable motor neurons. Importantly, when SNCA levels
were increased in a mouse model of motor neuron disease, the disease phenotype was sig-
nificantly reduced, including an extension in survival and reduction in motor neuron
pathology. Collectively, these results demonstrate that this approach can identify disease
modifiers that can reduce disease severity in models of motor neuron disease and poten-
tially identify new therapeutic targets.
Introduction
The term “motor neuron disease” refers to a group of disorders in which motor neurons are a
prominent pathological target. Such disorders are generally severely disabling and frequently
fatal within months to years of diagnosis. Effective treatments for many motor neuron diseases
are currently lacking. Motor neuron diseases can be categorized into various types. For exam-
ple, Amytrophic Lateral Sclerosis (ALS) affects upper and lower motor neurons and disease
onset is typically in adulthood between the ages of 30 and 50. While approxitamely 10% of
ALS cases are familial, the majority of new cases are sporadic[1]. Spinal Muscular Atrophy
(SMA) refers to a type of motor neuron disease that is caused by homozygous loss of the
SMN1 gene[2, 3], resulting in the loss of lower motor neurons. Due to the presence of an addi-
tional partially functional copy of SMN, termed SMN2, which can exist in a range of copy
numbers, SMA severity can vary widely[4]. However, the most common form of this disease
has an onset of less than 6 months of age and a life expectancy of under 2 years without signifi-
cant respiratory support. Spinal and Bulbar Muscular Atrophy (SBMA) is an X-linked motor
neuron disease caused by an expansion of a trinucleotide repeat in the androgen receptor
gene[5]. SBMA also appears to result in the degeneration of lower motor neurons with onset
between 30 and 50 years of age. SBMA disease progression is typically slower than other types
of motor neuron diseases and patients typically have normal life expectancies.
Distinct motor neuron diseases with their own specific cause, onset and prognosis are
united by the common vulnerability and loss of motor neurons. Importantly, however, in each
disease motor neurons are not uniformly vulnerable. In both patients and animal models,
some motor neuron populations are lost very early in the disease, whilst others remain remark-
ably intact, even at late stages of disease. For example, in SMA the pattern of motor neuron
pathology is highly predictable. This has been extensively characterised in mouse models of
the disease[6–9]. The pattern of selective vulnerability in patients is less-well documented but
it has been described as highly stereotyped, even within muscles groups[10]. One of the last
groups of motor neurons to be affected are those supplying the muscles of the face, in particu-
lar those supplying the extra-ocular muscles[11]. The location of disease onset in patients with
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ALS is more variable; however, there appears to be a sparing of the motor neurons which sup-
ply the extra-ocular muscles[12]. This finding has been corroborated in mouse models of ALS
in which there appears to be a marked differential vulnerability of specific cranial nerve nuclei
[13, 14]. Therefore, despite subtleties in the different patterns of selective vulnerability between
different motor neuron diseases, there are also important pathologenic similarities. This point
was highlight in a study by Comley et al., demonstrating a shared pattern of selective vulnera-
bility in mouse models of ALS and SMA [6]. Recent work has also shown significant overlap in
the molecular mechanisms which govern distinct subtypes of motor neuron diseases [15].
Identifying the common mechanisms giving rise to selective protection or vulnerability of
motor neurons will provide important biological insight into motor neuron development, but
can also lead to the identification of novel therapeutic targets for motor neuron diseases.
This observed selective vulnerability of motor neurons creates a valuable opportunity to
investigate the mechanism of motor neuron vulnerability in motor neuron diseases. Indeed,
we have recently utilised this observation to investigate the transcriptional differences occur-
ring pre-symptomatically in a mouse model of SMA[16]. In this study, motor neuron vulnera-
bility was defined by the level of pathology observed at the neuromuscular junction (NMJ).
Pathology at the NMJ was defined as denervation, pre-synaptic swelling and decrease in pre-
and post-synaptic complexity. We identified an increase in vulnerability in the NMJs from the
abdominal muscles compared to those in the cranial muscles. The motor neuron cell bodies
which corresponded to these differentially vulnerable NMJs were isolated and RNAseq was
performed to generate transcriptional profiles for abdominal and cranial motor neurons from
SMA and WT mice. The purpose of this study was to identify transcriptional changes which
correlate with a decrease in Smn levels, and those which correlate with an increase in motor
neuron pathology. However, an additional benefit of this screen was to profile the transcrip-
tomes of vulnerable and resistant motor neurons from wild-type mice. We suggest that genes
which are differentially regulated between these two populations of healthy motor neurons
have the potential to be important modifiers of disease. Indeed, identifying the modifiers in
selectively resistant motor neuron pools which are responsible for their decreased their vulner-
ability could provide key insight for the development of strategies to protect more vulnerable
motor neurons.
This idea has previously been exploited by a number of independent groups who have
observed predictable patterns of selective vulnerability in different motor neuron diseases, and
aimed to identify transcriptional changes between vulnerable and resistant motor neuron
pools[17–19]. Each of these studies identified motor neurons which were predictably vulnera-
ble or resistant in SMA, SBMA or ALS patients or animal models, and used laser capture
microdissection to isolate these equivalent motor neurons from neurologically healthy
humans, wild-type rats or mice. These 3 screens have identified a large number of transcrip-
tional changes between differentially vulnerable motor neurons in healthy individuals.
The transcriptional profiles from these screens, therefore, represent a valuable set of data,
detailing expression changes occurring between vulnerable and resistant motor neurons from
a range of species and ages, all from healthy individuals. Such changes cannot, therefore, be
due to any pathology, and are rather reflective of instrinsic differences between motor neuron
pool which may alter their vulnerability to pathological situations. In our search for transcrip-
tional modifiers of motor neurons, we suggest that common features between these transcrip-
tional changes have a high chance of being modifiers of motor neuron pathology. Features
which are common across transcriptional screens are also likely to be modifiers across multiple
motor neuron diseases, rather than just one MND subtype. Gaining knowledge of these modi-
fiers will give insight into shared mechanism of disease, and therefore potential shared thera-
peutic options.
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In this study, we compared the transcriptome of vulnerable (innervating abdominal mus-
cles) and resistant (innervating cranial muscles) motor neurons from P10 wild-type mice
which are differentially vulnerable in mouse models of SMA. In order to refine this data set,
we reanalyzed the raw data from 3 published independent microarray screens on healthy but
differentially vulnerable neurons and compared it to our RNAseq data. We identified 6 tran-
scripts that share common directional changes in all 4 screens: CELF5, Col5a2, PGEMN1,
SNCA, STMN1 and HOXa5. Functional clustering of the transcripts that were changed in 2 or
more of the 4 screens revealed an enrichment for synaptic and axonal transcripts. Introduction
of the differentially expressed genes into a Drosophila model of ALS8 rescued hallmarks of the
neurodegenerative phenotype, demonstrating that the differentially expressed genes can func-
tion in disease-relevant pathways. Due to the lack of Drosophila homologue for SNCA, and
because of evidence from the literature implying SNCA may have neuroprotective qualities,
we investigated whether increasing levels of SNCA could amleriorate the phenotype in a
mouse model of motor neuron disease. ScAAV9-SNCA was delivered to a mouse model of
SMA, resulting in a significant decrease in disease severity, including an extension in survival
and increased weight gain. Importantly, NMJ pathology in scAAV9-SNCA treated mice was
significantly improved, providing evidential support for the notion that differentially
expressed genes from susceptible motor neurons can serve as disease modifiers.
Results
Differential levels of neuromuscular junction pathology correlate with
differential expression levels of a large number of transcripts
Differentially vulnerable motor neurons have been reported in patients and in mouse models
of SMA [6–11]. In the Smn2B/- SMA mouse model, selective vulnerability can be observed at
the neuromuscular junction (NMJ). Analysis of NMJs in the abdominal muscles revealed a
high level of denervation, alongside other markers of pathology such as neurofilament accu-
mulation, shrinkage of endplates and a decrease in endplate complexity (Fig 1)[8, 16]. This
represents a “vulnerable” population. Analysis of a group of cranial muscles, which are inner-
vated by motor neurons residing in the facial nucleus of the brainstem, show no evidence of
denervation and minimal evidence of other markers of NMJ pathology and therefore represent
a “resistant” population (Fig 1) [8, 16].
In previous work, we used intramuscular injection of dextran molecules to trace the motor
neurons’ cell bodies which correspond to these differentially vulnerable groups of NMJs[16].
Cell bodies were isolated by laser capture microdissection and RNAseq was performed on
extracted RNA. Parallel experiments were performed on wild-type and Smn2B/- SMA mice.
This study[16] focused on the differences between SMA and WT mice at a pre-symptomatic
time point (P10). However, this work also produced a transcriptional profile of thoracic (vul-
nerable) and cranial (resistant) motor neurons from wild-type mice. In the current study, we
address the hypothesis that the transcriptional changes occurring between vulnerable and
resistant motor neurons in wildtype mice reflect intrinsic differences which contribute to the
differential vulnerability observed in the mouse model of disease. Comparison of the transcrip-
tional data between resistant and vulnerable motor neurons from wild-type mice resulted in
910 significantly altered transcripts with a fold change of>1.5 fold, with 218 up-regulated and
692 down regulated in vulnerable versus resistant motor neurons (Table 1, S1 Table). Func-
tional clustering of these transcriptional changes using DAVID bioinformatics resources ver-
sion 6.8 revealed an enrichment for extracellular matrix and glycoproteins (Table 2).
SNCA is a modifier in motor neuron disease
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Comparison of RNAseq data with published screens refines list of
potential modifiers
This screen has identified a large number of transcriptional changes. However, it is difficult to
differentiate those which merely correlate with differential vulnerability from those which
actually contribute to differential vulnerability. In order to identify those changes which had
Fig 1. Intermuscular variability in the levels of neuromuscular junction pathology in the Smn2B/- mouse model of SMA. A) Schematic
diagram showing location of muscles which were innervated by either vulnerable or resistant motor neurons in a mouse model of SMA.
Vulnerable muscles, as defined by increased neuromuscular junction (NMJ) pathology, include: external and internal oblique; transversus
abdominis; and rectus abdominis. Resistant muscles, as defined by a low level of NMJ pathology, include: levator auris longus; auricularis
superior; and adductor auris longus. B) Confocal micrographs showing NMJs with the pre-synaptic terminal labeled with antibodies against
neurofilament (NF; Green) and synaptic vesicle protein 2 (green) and the muscle endplate labeled with alpha-bungarotoxin (red) from rectus
abdominis and auricularis superior muscles. Note that in the wild-type abdominal and Smn2B/- cranial muscle, all endplates appear fully
innervated where each endplate is covered by the pre-synaptic terminal labeled with SV2 and NF. In the rectus abdominis from the Smn2B/-,
mouse there is evidence of significant NMJ pathology, as evidenced by endplates lacking a pre-synaptic terminal (white arrow heads). Scale
bar = 40μm.
https://doi.org/10.1371/journal.pgen.1006680.g001
SNCA is a modifier in motor neuron disease
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the highest probability of being modifiers and perhaps play also a causative role in motor neu-
ron pathology, we compared the results of our screen with the results of other screens on dif-
ferent populations of differentially vulnerable motor neurons which have been previously
published (Table 3).
Raw microarray data were re-analysed and a list of differentially expressed genes for each
screen was generated. As screens were performed in different species, genetic homologues
were identified, and all genes were listed corresponding to the mouse official gene symbol.
Comparison of the results of the 3 microarray studies with our own RNAseq data revealed a
large number of common changes, with the majority occurring the same direction of change
(Fig 2). Transcriptional changes from these 4 transcriptional screens were sorted based on
direction of change. This resulted in the identification of 595 transcripts which were altered in
a common direction in 2 screens (S2 Table), 62 transcripts which were common in 3 screens
(S3 Table) and 6 transcripts which were common in all 4 screens (Table 4). Functional cluster-
ing of the transcriptional changes occurring in 2 or more screens revealed an enrichment for
axonal and synaptic proteins (Table 5).
Table 1. Top 20 transcriptional changes identified between vulnerable (abdominal) and resistant (cranial) motor neurons from P10 wild-type mice.
Gene Symbol Log Fold Change Q Value Gene Symbol Log Fold Change Q Value
Hoxc8 11.1 9E-06 Ptgds -11.0 0E+00
Hoxd8 10.4 1E-03 Tbx15 -10.0 9E-05
Hoxc9 7.8 6E-04 Glis1 -9.7 3E-04
Hoxa5 7.1 1E-07 Slc6a4 -9.6 1E-03
D930020B18Rik 6.8 1E-02 Tph2 -9.4 1E-06
Npy5r 6.8 2E-03 Omd -9.2 5E-02
BC023105 6.5 5E-03 Fam180a -8.9 9E-06
AU021034 6.3 5E-04 Gm15605 -8.8 1E-02
AV039307 6.2 2E-05 Cdh1 -8.7 2E-09
Mstn 5.6 1E-04 Insm1 -8.6 9E-05
Hoxb7 5.5 3E-05 Nov -8.5 1E-13
Gm20520 5.4 2E-02 Moxd1 -8.5 3E-05
BC037032 5.4 1E-03 Slc17a7 -8.2 8E-05
Hoxd9 5.4 5E-03 Ogn -8.1 0E+00
Troap 5.3 2E-02 Gal -7.9 1E-04
Prss56 5.3 4E-02 Gxylt2 -7.6 5E-03
Thpo 5.2 2E-04 Thbd -7.5 2E-13
Mpz 5.2 2E-04 Trim58 -7.4 9E-11
Gm5077 5.0 3E-03 Cyp2f2 -7.3 4E-02
Glp1r 5.0 4E-04 Aldh1a2 -7.2 7E-11
https://doi.org/10.1371/journal.pgen.1006680.t001
Table 2. Top 5 functional clustering of transcriptional changes identified between vulnerable and
resistant motor neurons.
Functional Cluster Enrichment Score
Extracellular Matrix 22.8
Glycoprotein/Extracellular Region 22.1
Cell adhesion 9.04
Focal Adhesion 6.53
Pattern binding 5.86
https://doi.org/10.1371/journal.pgen.1006680.t002
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Differentially expressed transcripts modify the degenerative eye
phenotype in a Drosophila model of ALS8
To determine whether the identified transcripts can modify neurodegenerative pathways, a
Drosophila model of ALS was used to functionally validate the candidate genes by driving
expression of the candidate genes or by transiently knocking-down expression. The purpose of
this screen was to determine whether a significant number of transcripts identified here were
capable of modifying the phenotype in an independent model of neurodegeneration induced
by an ALS causing mutation. Transcripts were selected that either changed in 3 or more of the
transcriptional screens (Table 4 and S2 Table) or were featured in one of the two top functional
clusters (axonal or synaptic transcripts) (Table 5). In this model, a Drosophila line expresses
the P58S mutation in the VAMP associated protein B gene (VAPB). This is equivalent to the
P56S mutation in human VAMP which is a causative mutation of human motor neuron dis-
ease, including ALS8 [20]. This mutation has been shown to affect a range of cellular processes
which have been implicated in MND, including the unfolded protein response, endocytosis,
vesicular trafficking, mitochondrial defects and autophagy [21–26]. The Drosophila homo-
logue of VAPB is termed VAP-33-1, or DVAP. In previous work, DVAP-P38S expression was
driven in the eye of Drosophila using the UAS/GAL4 system[27], with an eyeless-GAL4
(ey-GAL4) driver. This resulted in a roughness of the adult Drosophila eye and a significant
Table 3. Summary of independent screens on differentially vulnerable motor neurons.
Paper Differentially vulnerable
in
Vulnerable Resistant Source
Hedlund et. al. 2010 [18] SMBA/ALS/SMA Cervical MNs Occulomotor/ Abducens
nucleus
Wild-type adult rat
Brockington et al., 2013
[17]
ALS Cervical MN Occulomotor Nucleus Neurologically normal human (59–67
YOA)
Kaplan et al., 2014 [19] ALS Lumbar spinal cord
(L5)
Occulomotor Nucleus P7 wild-type mice
https://doi.org/10.1371/journal.pgen.1006680.t003
Fig 2. Comparison of 4 independent screens on differentially vulnerable motor neurons reveals a
large number of common transcriptional changes. Scatter plot showing the fold change of transcripts
which were differentially expressed in differentially vulnerable motor neurons in the RNAseq performed by
Murray et al., 2015 [16] and in the microarray study on differentially vulnerable motor neuron performed by
Brockington et al., 2013 [17] (green), Kaplan et al., 2014 [19] (blue) and Hedlund et al., 2010 [18](red).
Numbers denote number of number of common transcriptional screens within each quadrant of the plot. Note
that the majority of changes occur with a common directional change i.e. fall within the bottom left or top right
quadrant of the graph.
https://doi.org/10.1371/journal.pgen.1006680.g002
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reduction its size, which could be attributed to a decrease cell survival[28]. This model and the
eye phenotype readout has previously been used in a large-scale enhancer and suppressor
screen for genetic modifiers of ALS8 pathology [23].
As outlined above, for this in vivo validation, we chose to include all transcripts which were
changed in 3 or more screens, as well as those pertaining to the top two functional clusters, of
axonal or synaptic transcripts. This resulted in a list of 160 transcripts. Drosophila homologues
were predicted for each transcript using the DRSC Integrative Ortholog Prediction tool
(http://www.flyrnai.org/cgi-bin/DRSC_orthologs.pl). Results were filtered to return only the
best match where more than one homologue was found and restricted to those with a DIOPT
score of greater than 2. Where more than one homologue was found with an equivalent
weighted score, all potential homologues were included. From the 160 transcripts listed, we
identified an homologue for 116, which includes 39 transcripts up-regulated and 77 down reg-
ulated transripts in vulnerable motor neurons.
For transcripts which were up-regulated in vulnerable motor neurons, we identified publi-
cally available lines carrying RNAi constructs to knock down transcripts of interest. For the
majority of lines (38/46), we selected those with zero off target effect predicted. For a small
number of lines this was not possible. In this case, lines with the minimum number of off tar-
get effects were used. For transcripts which were down-regulated in vulnerable motor neurons,
we identified publically available lines carrying a P-element insertion which, based on the posi-
tion and orientation, would be predicted to result in an over expression of the transcripts of
interest.
From this, 66 publically available lines were available to decrease or increase the expression
of these transcripts respectively (Table 6). Lines designed to decrease or increase expression
Table 4. Transcriptional changes which are common across all 4 screens on differentially vulnerable motor neurons.
Fold Change
Brockington Kaplan Murray Hedlund
Celf5 -3.3 -1.4 -2.0 -2.7
Col5a2 -3.1 -3.8 -3.9 -2.1
Pgrmc1 -1.5 -0.8 -1.6 -2.6
Snca -1.3 -1.1 -1.8 -2.0
Stmn1 -1.4 -0.8 -1.6 -1.0
Hoxa5 2.9 3.5 7.1 3.7
https://doi.org/10.1371/journal.pgen.1006680.t004
Table 5. Functional clustering of transcriptional changes which are common in 2 or more of the
screens on differentially vulnerable motor neurons.
Functional Cluster Enrichment Score
Neuron projection/Axon 8.00
Synapse/Synaptic Vesicle/Cell junction 7.80
Synaptic transmission 3.91
Homeobox/DNA binding 3.89
Extracellular Matrix 3.54
Ionic Channel 3.52
Synaptic vesicle 3.21
Membrane Fraction 3.08
Clathrin Coated Vesicle 2.93
Glycoprotein 2.91
https://doi.org/10.1371/journal.pgen.1006680.t005
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our candidate modifiers were crossed with DVAP-P58S flies. Those lines which increase the
size of the eye compared to the DVAP-58S flies were categorised as suppressors, and those
which decreased the size of the eye were categorised as enhancers of the neurodegenerative
phenotype. Overall, 11 transcripts modified the neurodegenerative eye phenotype observed in
DVAP-P58S flies, with 7 suppressors and 4 enhancers (Fig 3). Overall, 17% of transcripts dis-
played an ability of modify the phenotype. Whilst it is difficult to draw direct parallels to other
screens, previous screen using Drosophila models of motor neuron disease or disease causing
Table 6. Mouse genes and their Drosophila homologue which were tested in the DVAPP-P58S Drosophila screen.
Mouse symbol fly symbol VDRC/ Bloomington Stock number Mouse symbol fly symbol VDRC/ Bloomington Stock number
Up-regulated in vulnerable motor neurons Down-regulated in vulnerable motor neurons
Altered in > 3 screens
Hoxb7, hoxd8 Antp 101774 Hdgfrp3 CG7946 22394
Spock1 CG13830 44584 Reps2 Reps 15935
Pygm CG7180 34369 Rgs8 Dhit 28396
Hoxc4 Dfd 50110 Cbln1 Capr 16833
Fryl fry 103569 Postn Fas1 19855
Glra1 GluClalpha 105754 En2 inv 26891
Spsb1 gus 8688 Rev3l mus205 22360
Hoxa5 Scr 105412
Pacsin3 Synd 40018, 104580
Isl2 tup 103585
Synaptic or Axonal transcripts altered in >2 screens
AnxA2, AnxA6 AnxB10 36107 SLC11A2 Mvl 19886
AnxA2, AnxA6 AnxB11 101313, 29693 SLC7A3 slif 19906
AnxA2, AnxA6 AnxB9 106867 CRMP1 CRMP 40953
ATP1A1 Atpalpha 12330 CAMK2A CaMKII 22325
LCP1 CG12104 107189 CHL1 CG11403 33544
TESC CG14362 22733 NCAM1 Fas2 11231
SLC6A5 CG5549 8222 SLC7A3 CG5535 27953
CYB5R3 CG5946 110688 SOCS7 Socs36E 27006
GABRA2 CG8916 9138, 101633
SLC6A5 DAT 105064, 106961
GPC1 dlp 29375, 29374
DCTN2 Dmn 23726, 23728
LCP1 Fim 6276, 46028
GNA14 Galphaq 105300
GNG12, GNG2 Ggamma1 28844
GABRA5 Grd 5329
NRP2 Hml 37005, 37006
ITGA7 mew 44890, 109608
MMP16 Mmp1 101505
MMP17 Mmp2 107888
ABCC3 MRP 7164, 105419
PRKACA Pka-C1 101524
ARHGDIA RhoGDI 46154, 46155
KCNA1 Sh 104474, 23673
SLC9A3R2 Sip1 16108, 16958
STMN2 stai 977, 13502
https://doi.org/10.1371/journal.pgen.1006680.t006
SNCA is a modifier in motor neuron disease
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Fig 3. In vivo validation of transcripts in a Drosophila model of ALS8. A) Images show eyes from wild-
type, DVAP-P58S (carrying ALS8 patient mutation), DVAP-P58S Dfd (AL8 patient mutation with decreased
expression of Dfd, the Drosophila homologue of Hoxc4) and DVAP-P58S Dfd (AL8 patient mutation with
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mutations, and performing unbiased screen to identifiy modiers have resulted in 0.4 to 4% of
genes being identified as enhancers or suppressors. Our increased hit rate compared to these
unbiased or enriched suggests that this bioinformatics approach has led to a list which is
enriched for disease modifying genes. This suggest that this approach is identifying relevant
transcripts which are capable of modifying neurodegenerative pathways associated with motor
neuron disease.
Over expression of alpha-synuclein modifies phenotype in a mouse
model of SMA
Alpha-synuclein (SNCA) was consistently decreased in vulnerable motor neurons across all
four screens. This was of particular interest as a decrease in SNCA levels have been reported in
SMA patient spinal cord, patient fibroblasts and NSC-34 motor neuron-like cells [29]. There
are also a number of studies indicating that, in certain scenarios, over expression of SNCA can
be neuroprotective[30–33]. As SNCA is a strong candidate to modify neuronal pathology, we
sought to further investigate the effects of SNCA over expression in models of motor neuron
disease. Unfortunately, there is no homologue for SNCA, which makes the effect of over
expression of SNCA in DVAP-P58S flies difficult to interpret. For this reason we turned to a
mammalian model, and sought to determine the impact of SNCA transient expression in the
Smn2B/- mouse model of SMA. To provide widespread expression of the SNCA transgene, an
scAAV9-SNCA vector was developed. AAV9 has a broad tropism for many tissues within the
periphery and the central nervous system, including astrocytes and neuronal lineages [34]. At
postnatal day 1, a single injection of 1e11 or 3e11 viral particles of scAAV9-SNCA was delivered
via an intracerebroventricular injection into the Smn2B/- mouse model of SMA. The lower dose
was selected based upon the amount of vector that provides a robust phenotypic rescue using
scAAV9-SMN[35]. Injection of 1e11 viral particles scAAV9-SNCA has no discernable effect on
life span or weight gain, however, the higher dose of 3e11 viral particles resulted in an ~88%
(23 day) increase in median life span and a significant increase in average body weight from
approximately P20 onwards (Fig 4A and 4B). Since the initial transcriptomic screen was
predicated upon the differential pathology observed at the NMJ, we next examined whether
scAAV9-SNCA treatment improved the NMJ phenotype in SMA mice. Importantly, analysis
of NMJs from P18 scAAV9-SNCA injected mice revealed a significant increase in the percent-
age of fully occupied endplates compared to untreated controls, indicative of a decrease in
denervation and motor neuron pathology (Fig 4C and 4D).
Together this work demonstrates that in a mouse model of SMA, over expression of SNCA
can impact upon the neurodegenerative pathways, and has the capacity to extend lifespan and
ameliorate the phenotype. This result is a clear proof of principle that this approach can iden-
tify relevant phenotypic modifiers that have the capacity to impact disease development in an
important model of neurodegeneration.
decreased expression of Nrbp1) Drosophila. Note the decrease in eye size observed in DVAP-P58S flies.
This phenotype was supressed by decreased expression of dfd, and enhanced by decreased expression of
Nrbp1. B) Bar chart (Mean ± SEM) showing the area (mm2) of the eye in Drosophila lines which over or under
express specified transcripts in DVAP-P58S flies. ***P<0.001, **P<0.01 by ANOVA with Holm-Sidak’s post
hoc test. N = approx. 12 flies per group with each value reflecting average of 2 eyes per fly. C) Table details
the transcripts which were identified as modifiers of the eye phenotype in DVAP-P58S flies, denoting the
Drosphila official gene symbol, the official gene symbol of the mouse homologue and the directional change
observed in vulnerable motor neurons in the independent transcriptional screens [16–19]. For those
transcripts which were decreased in vulnerable motor neurons, their expression was increased in
DVAP-P58S flies, and for those transcripts which were increased in vulnerable motor neurons, their
expression was decreased in DVAP-P58S flies.
https://doi.org/10.1371/journal.pgen.1006680.g003
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Fig 4. Overexpression of SNCA ameliorate phenotype and neuromuscular junction pathology in the
Smn2B/- mouse model of SMA. A, B) Kaplan Maier plot (A) and weight curve (B) showing profile of control
(Smn2B/+; black) and untreated Smn2B/- (red) compared to mice treated with a low dose (1e11; blue) or high
dose (3e11; green) of AAV9 expressing SNCA. Note that while the low dose only increases weight gain
(Student’s t-test p < 0.0001, the high dose of AAV9-SNCA significantly increased weight (Student’s t-test
p<0.0001) and lifespan in the Smn2B/- mouse model (Mantel-Cox Survival Curve Comparison Test
p = 00027). C) Confocal micrographs showing NMJs with the pre-synaptic terminal labeled with antibodies
against neurofilament (NF; red) and synaptic vesicle protein 2 (red) and the muscle endplate labeled with
alpha-bungarotoxin (green) from the transversus abdominis muscle from P18 mice. Note the presence of fully
(arrowhead) and partially (arrow) denervated endplates in the untreated Smn2B/- mouse which were less
commonly observed in the Smn2B/- mouse treated with high dose AAV9-SNCA. Scale bar = 20μm. D) Bar
chart ± SEM showing the increase in the percentage of fully occupied endplates in untreated Smn2B/- mice
(black bars) compared to Smn2B/- treated with high dose AAV9-SNCA. ***P <0.001 by Mann-Whitney U test
where n = 4/8 mice/muscles per group.
https://doi.org/10.1371/journal.pgen.1006680.g004
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Discussion
In this study we have compared multiple screens performed across 3 species to generate a list
of common differentially expressed transcripts. We have used a Drosophila model to demon-
strate that a high proportion of these can modify the neurodegenerative phenotype caused by a
human ALS8 mutation. Importantly we have also shown that over expression of SNCA can
extend life span and decrease NMJ pathology in a mouse models of SMA. This demonstrates
that this approach can identify relevant phenotypic modifiers. It also suggests that SNCA is an
exciting candidate which deserves further attention, and that the remaining candidate list is
likely to have some exciting transcripts within it.
The use of transcriptional screen methodologies to dissect the mechanism of disease is
central in the study of most pathologies. Screening techniques have been instrumental in iden-
tifying affected pathways and perturbed cellular functions. However, when the intended reso-
lution of a transcriptional screen is to identify individual differentially expressed transcripts, it
can be difficult to separate those which are changed due to the process of disease, and those
which are changed to compensate for a loss of function or due to the altered activity of the
organism, organ or cell. Even at pre-symptomatic stages of disease, there are likely to be tran-
scriptional changes occurring as a secondary response to the original pathology. A significant
advantage of the current work is to compare the transcriptomes of distinct differentially vul-
nerable motor neuron populations from normal healthy individuals. This approach allows us
to identify those changes which are present in a normal situation, but could potentially impact
upon the disease process. Clearly dissecting apart those which are changed by coincidence
from those which actually have the potential to modify disease is challenging. This is before
the added challenge of identifying those which are actually relevant in humans. However, by
comparing across 4 screens, across 3 or more different MNDs, and across 3 species, including
humans, we feel we have created an experimental design which has a high chance of identify-
ing clinically relevant modifiers of motor neuron disease.
Common regulators of vulnerability in motor neuron disease
A number of studies have implicated SMN1 and SMN2 copy number in the incidence of spo-
radic ALS[36]. The observation that ALS causing mutations in FUS and TDP-43 can alter the
localisation and associations of Smn has also led to some suggestion of shared mechanism
between diseases[36]. Furthermore, although there are certainly some important distinctions
in the patterns of selective vulnerability between distinct motor neuron diseases, there are
some common themes, in that motor neurons originating in brainstem motor nuclei appear
consistently comparatively spared, particularly those supplying the extra-ocular muscles [6,
11–14]. There is therefore good reason to suppose that the mechanisms mediated selective
vulnerability in motor neuron disease can, to at least some extent, be shared. In an extension
of this, resultant neuroprotective therapies should have the potential to benefit a range of
conditions.
The work presented in this study has generated some exciting candidates to be cross-disease
modifiers. Aside from SNCA (discussed below) there are a number of transcripts which war-
rant further investigation. CUGBP, elav—like family member 5 (CELF5) belongs to a family of
developmentally expressed RNA binding proteins, with a proposed role in pre-mRNA splicing
[37]. As this is a function shared by many MND causing mutations, it is easy to generate
hypothesis about how differential CELF5 levels may modify pathology. Progesterone receptor
membrane component 1 (Pgrmc1) is best characterized due to its role in cancer. However, its
oncogenic actions are due in part to its ability to promote cell survival and inhibit apoptosis.
PGRMC1 is thought to mediate the protective effects of progesterone on rats modeling
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Alzheimer’s disease via inhibition of the mitochondrial apoptotic mechanism[38]. It has also
shown to be an important mediator in the neuro-protective effect of a synthetic progesterone
in the degenerative eye disease retinitis pigmentosa[39]. The observation that Pgrmc1 is
decreased in all 4 screens in vulnerable motor neurons could be associated with the increase in
cell death of this subpopulation of cells. Stathmin (Stmn1) is a well characterized microtubule
binding protein and as such, has important roles in cellular functions dependent upon micro-
tubules, including in mitosis, motility, process formation and intracellular transport[40].
Stathmin has been shown to be dysregulated in a mouse model of ALS, and knockout of stath-
min produces a mouse displaying peripheral and central axon degeneration [41, 42]. Interest-
ingly, decreased stathmin levels have previously been shown to increase body weight, motor
performance and NMJ maturation is a mouse model of SMA[43]. Therefore amongst our top
differentially expressed transcripts we have some very exciting candidates to be modifiers of
motor neuron diseases.
How does SNCA function as a disease modifier
SNCA performs a number of cellular roles, but has been implicated as a causative factor of Par-
kinsons disease [44]. Mutations in SNCA are strongly associated with aggregate formation,
leading to the degeneration of nigrostriatal neurons, causing the well characterised and com-
mon disorder of the basal ganglia. Although the pathogenic mechanisms of SNCA aggregates
in Parkinson’s is relatively well characterised, the normal function of SNCA is less well defined.
It is known to be a small protein of about 140 amino acids localising to the pre-synaptic termi-
nal [45]. It is thought to have an important role in neurotransmitter release. Indeed, over
expression of SNCA in primary hippocampal neuron cultures and hippocampal slice culture
has been shown to inhibit synaptic vesicle exocytosis, potentially by slowing the recycling of
synaptic vesicles and decreasing the number of vesicles in the readily releasable pool[46]. Fur-
thermore, alpha-synuclein knockout mice display an increased rate of vesicle filling under
repetitive stimulation[47]. How then might this role of SNCA be a protective modifier in
motor neuron diseases? The idea of SNCA possessing neuroprotective qualities is not novel.
Whilst some have suggested that over expression of wild-type SNCA could increase vulnerabil-
ity to certain insults such as oxidopamine (a toxin specific to dopiminergic neurons)[33],
other work has shown that increased SNCA can decrease toxicity caused by the pesticide para-
quat [32], the apoptotic ages staurosporin and etoposide [30] and oxidative stress induced by
hydrogen peroxide [31]. The resistance to oxidative stress observed was proposed to be due to
a down regulation of the cell stress induced c-Jun N-terminal kinase pathway which promotes
apoptosis[31]. The mechanism by which SNCA could be a protective modifier in the context
of this study is currently unclear. However given the multiple scenarios in which SNCA has
been shown to be neuroprotective, further work is justified to explore this mechanism.
Why are transcripts differentially expressed in motor neurons?
As the screens detailed in this report have been performed in exclusively healthy motor neu-
rons, which happen to be differentially vulnerable in disease, the transcriptional changes
which we are reporting likely occur for reasons unrelated to motor neuron pathology. It is
therefore important to consider why the transcriptional changes exist. These transcriptional
changes may reflect differences in the development, function, physiology or anatomy of the
individual motor neurons. For example, we might suggest that cranial motor neurons gener-
ally have a shorter axonal length that those located elsewhere in the body. It is also possible
that they have have other structural differences such as a more elaborate dendritic tree, or a
different proportion of axodendritic or axosomatic synpases. The potential differences in form
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and function between motor neuron pools are seemingly endless. We can also only currently
hypothesize about how changes in development, form or function could result in a selective
sparing in a pathological situation. For this reason, rather than dismissing transcriptional
changes occurring between differentially vulnerable motor neuron as, most likely due to a dif-
ference in the development, location or function of a given pool of motor neurons, it may be
useful to use the list of transcripts identified to generate ideas about how this can impact upon
the anatomy and physiology of the motor neuron. Indeed, the observation that a large number
of HOX genes were differentially expressed between differentially vulnerable motor units may
be attributed to the different location of the different motor neuron pools. However, it may be
that the actual difference in location, and the associated differences in anatomy and physiology
actually contribute to their differentially vulnerabililty. Determining the reasons and conse-
quences of the differential transcriptional expression may lead to to a broader understanding
of what fundamental differences make a motor neuron more or less vulnerable during disease.
We therefore suggest that future efforts, to understand the impact of differential expression of
specific transcripts or alterations in specific cellular pathways relate to the development, physi-
ology and anatomy of specific motor neuron pools may be fruitful in our search to understand
the phenomenom of selectively motor unit vulnerability of motor neuron disease.
Conclusions
In this work we have employed a novel approach to identify transcripts that are functionally
significant in motor neuron disease-relevant pathways. We have demonstrated that at least
one of these candidates can modify the phenotype in a mouse model of SMA, and believe that
the remaining list contains additional candidates that warrant further examination. Based
upon the design of the experiments, these modifiers may functionally interact in more than
one disease context and therefore have the ability to provide protection to motor neurons in a
variety of neurodegenerative conditions. Future efforts to identify potent modifiers and their
mechanisms of action will provide insight into the mechanism of disease, and aid in the devel-
opment of therapeutic agents which can slow the degeneration of motor neurons in MND.
Materials and methods
Data acquisition and analysis
RNAseq data, profiling the transcriptome of cranial and abdominal motor neurons from P10
wildtype mice was obtained as detailed in Murray et. al.[16]. Further analysis of this data was
allowed by generous agreement with Dr Rashmi Kothary. The raw microarray files detailing
transcriptional data published in Kaplan et al., 2014 and Brockington et al., 2013 were down-
loaded from the gene expression omnibus using the reference numbers GSE52118 and
GSE40438 respectively[17, 19]. Raw microarray files from the study by Hedlund et al. were
generously provided by Dr Eva Hedlund[18].
Following acquisition of raw microarray data sets, data was normalised using a quantile
method, and genes which were differentially expressed within each screen were identified. All
genes with an adjusted P value of>0.05 were eliminated from the study. For RNAseq data,
transcripts had been identified by alignment to the mouse mm9 genome assemble in Murray
et. al.[16], and relative transcript levels were compared using CuffDiff software v1.3 using the
UCSC transcript model. Significance was considered with an adjusted P value of<0.05 and a
greater that 1.5 fold change in expression level. HomoloGene was use to identify the genetic
homologue between species. Data was sorted in excel to reveal changes which occurred in a
common direction in 2 or more screens.
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Screening methods and Drosophila husbandry
Genetic schemes and Drosophila husbandry were performed as detailed in Sanhueza et al.,
2015[23]. Briefly, the tester line carrying both the ey-Gal4 driver and the UAS-DVAP-P58S
transgene on the second chromosome was crossed individually with RNAi and EP lines with
the potential of overexpressing the gene of interest. The F1 progeny was analyzed for the sup-
pression or the enhancement of the DVAP-P58S induced small and rough eye phenotype. In
particular, 8–10 males of either the EP or RNAi line were mated to 10–15 females of the ey-
Gal4, DVAP-P58S/CyO ALS8 fly stock. After two days, adults were transferred to a new vial to
have a duplicate cross. Embryos from both vials were raised at 29˚C in a water bath to maxi-
mize the effect of the Gal4. Both enhancing and suppressing effects of the DVAP-P58S-
induced eye neurodegenerative phenotype were assessed in these conditions. RNAi lines were
acquired from the Vienna Drosophila RNAi line Center while EP and EPgy lines were obtained
from the Drosophila Bloomington Stock Center.
Mouse maintenance
For analysis of differentially vulnerable muscles, Smn2B/- mice and wildtype controls on a
C57Bl6 background were maintained in the animal facilities at the University of Edinburgh.
Mice were sacrificed by overdose of inhalation anaethetic (isofluorane) and cervical disloca-
tion. All experiments were performed in accordance with the regulations set out by the UK
Home Office. For experiments requiring the administration of AAV9, all mice were housed
and handled in accordance with the Animal Care and Use Committees of the University of
Missouri. Smn2B/2B mice were a kind gift from Dr. R. Kothary (Ottawa, Canada). FVB Smn+/-
mice were purchased from the Jackson Laboratory. Mice were housed under a 12 hours light/
dark cycle and the colonies were maintained as heterozygote breeding pairs under specific
pathogen-free conditions.
Vector construction
293T HEK cells (ATCC CRL 3216, American Type Culture Collection, Manassas, VA, USA)
cultured in 4 10-floor cell factories until ~85% confluent. Cells were triple transfected with
Rep2Cap9 (Serotype 2 Rep proteins, Serotype 9 capsid proteins), pHelper (Adenovirus helper
constructs), and scAAV-CBA-SNCA using 25 kDa Polyethyleneimine (PEI) at a molar ratio of
1:1:1. Media was changed 24 hours after transfection, and cells were harvested at 48 hours after
transfection. Cells were suspended in 10 mmol Tris, pH = 8.0, lysed by 5 freeze-thaw-cycles in
liquid nitrogen, DNAse treated, and protease treated. CsCl crystals were added to the lysate
(0.631 g of CsCl per ml of the lysate) to generate a solution with a density of *1.4 mg/ml.
After incubation at 37˚C for 45 min, the solution was centrifuged at 4000 rpm in an Eppendorf
5810 R at 4˚C. Virus was purified from lysate by 3 rounds of density gradient centrifugation at
an average RCF of 158,000. High titer fractions were detected after each round of centrifuga-
tion using quantitative real-time PCR. The final fractions were dialyzed exhaustively against
phosphate buffered saline and stored at 4˚C until use.
Administration of AAV9 vectors
Viral delivery was performed by intracerebroventricular (ICV) injection using methods
described previously [48, 49]. Briefly, ICV injections were performed using sterilized glass
micropipettes. The needles were inserted perpendicular to the skull at the injection site
approximately 0.25 mm lateral to the sagittal suture and 0.5 mm rostral to the coronary suture.
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Immunofluorescent staining and quantification
For NMJ labelling, muscles were immediately dissected from recently sacrificed mice and
fixed in 4% PFA (Electron Microscopy Science) in PBS for 15 min. Post-synaptic AChRs were
labelled with α-bungarotoxin (BTX) for 30 min. Muscles were permeabilised in 2% Triton X-
100 in PBS for 30 min, then blocked in 4% bovine serum albumin (BSA)/1% Triton X-100 in
PBS for 30 min before incubation overnight in primary antibodies [Neurofilament (NF; 2H3)
—Developmental Studies Hybridoma Bank; synaptic vesicle protein 2 (SV2)—Developmental
Studies Hybridoma Bank; S100 –Dako; all 1:250] and visualised with Cy3-conjugated second-
ary antibodies [Cy3 goat anti-mouse; 1:250, Jackson]. Muscles were then whole-mounted in
Dako Fluorescent mounting media. Confocal microscopy was performed using a Nikon A1R+
Resonant Scanning System (Nikon) (10x and 40x objectives; 0.3 and 1.3 oil NA; Nikon A1R+
microscope; simultaneous image acquisition). 488 and 543 nm laser lines were used for excita-
tion. The resultant confocal Z-series produced in NIS Elements 2D Analysis software were
exported and merged using Fiji ImageJ software.
The percentage of fully occupied endplates was determined by classifying each endplate in a
given field of view either fully occupied (pre-synaptic terminal (SV2 and NF) completely over-
lies endplate (BTX)), partially occupied (pre-synaptic terminal only partially covers endplate
(BTX)), or vacant (no pre-synaptic label overlies endplate). At least 4 fields of view were ana-
lysed per muscle totalling >100 endplates per muscle.
All data was assembled and analysed using Microsoft Excel and GraphPad Prism.
Supporting information
S1 Table. Results from RNAseq comparing vulnerable (innervating the abdominal mus-
cles) and reistant (innevating the cranial muscles) motor neurons from P10 WT mice.
Table shows the ensembl ID (test-ID, gene_id), the official gene symbol (gene), the chromo-
somal location (locus), the average normalised read count from an N of 2 samples for resistant
(BS-WT) or vulnerable (SC_WT) samples, the log2 fold change, and the relevant statistics
(test-stat, P_value, Q-value, significant).
(XLSX)
S2 Table. Transcriptional changes which occurred in 3 of more of the included transcrip-
tional screens. Table includes the mouse official gene symbol and the log2 fold change identi-
fied in Brockington et al., Kaplan et al., Murray et al., and Hedlund et al.
(XLSX)
S3 Table. Transcriptional changes which occurred in 2 of more of the included transcrip-
tional screens. Table includes the mouse official gene symbol and the log2 fold change identi-
fied in Brockington et al., Kaplan et al., Murray et al., and Hedlund et al.
(XLSX)
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